|
|
Princeton Crossroads Corporate Center, 250 Phillips Boulevard, Suite 290
Ewing, NJ 08618 USA
phone:+1 (609) 359 3020
fax:+1 (609) 359 3015
|
|
| Symbol |
AIS |
| Exchange |
NYSE |
| Founded |
2001 |
| Employees |
27 |
|
|
| www.antarespharma.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Developing therapeutics through drug delivery systems |
|
| Management |
| Paul Wotton, Ph.D., President & CEO; Robert F. Apple, Executive Vice President and President of the Parenteral Products Division; Dario N. R. Carrara, Ph.D, Sr. Vice President and Managing Director; Kaushik J. Dave, R.Ph., Ph. D., MBA, Senior Vice President Product Development; Peter Sadowski, Ph.D., Senior Vice President Parenteral Products Division |
| |
|
|
|
|
|
|
|
| Keywords |
| transdermal delivery systems, reusable needle-free injection devices, hormone, small gauge needle, multi-use pen injector |
|
|
|
| Description |
|
Antares Pharma is committed to developing and commercializing novel therapeutic products utilizing their unique, advanced drug delivery systems. Their products are patient focused: they typically improve safety and efficacy, reduce side effects and enable us to deliver a lower dose. The advanced drug delivery systems of Antares Pharma are also well positioned for �life cycle extension� options. The company believes that they offer a distinct value to patients, physicians and our shareholders. |
|
| Products / Services |
The Company's current products include transdermal Advanced Transdermal Delivery (ATD(tm)) gels; fast-melt oral disintegrating tablets (Easy Tec(tm)); disposable minineedle injection systems (Vibex(tm)); and reusable needle-free injection systems (Medi-Jector VISION and Valeo(tm)).
|
|
| Technology / Differentiation |
| Antares Pharma's transdermal drug delivery platform deliver medication with less potential for skin irritation, while avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs. |
|
| Market / Customers |
Antare's device focus is specifically on the market for delivery of self-administered injectable drugs. The largest and most mature segments of this market consist of insulin for patients with diabetes and human growth hormone for children with growth retardation. According to industry sources, the worldwide insulin market is estimated to grow from $7.7 billion in 2005 to $14.6 billion in 2010, of which $2 billion in 2010 is inhaled insulin.
|
|
| Competitors / Substitutes / Alternatives |
Bioject Medical Technologies, Bentley Pharmaceuticals, Aradigm, Cellegy Pharmaceuticals, Cardinal Health, CIMA Laboratories, Laboratoires Besins-Iscovesco, MacroChem Corporation, NexMed, Novavax
|
|
| Strategy |
Antares Pharma key strategies are to validate early technologies/platforms with development, leverage proprietary platforms to develop internal pipeline, out license product rights in larger more mature sectors, commercialize products in niche physician sectors of dermatology,pain, urology, CNS, and women's health, acquire or license complimentary products or technology and market products in niches or seek marketing partners.
|
|
| Status |
| Late in 2005 Antares announced their first commercial deal with a subsidiary of Teva Pharmaceuticals for their novel injector device with their drug. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members